Popular search terms:
Search Results
75 results found-
As is with other influenza vaccines, children who have received the appropriate course of FLUAD® Pediatric or another seasonal influenza vaccine are considered to be primed.
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/20252026-fluad-product-monograph-rev04-avril-2025.pdf -
FLUCELVAX® Trivalent Influenza Vaccine FLUCELVAX® Trivalent Influenza Vaccine QUAD TIV1c4 TIV2c4 QUAD TIV1c4 TIV2c4 N=663 N=330 N=327 N=656 N=340 N=336 Local Adverse Reactions Injection site 45 (<1) 37 (<1) 41 (0) 22 (0) 19 (0) 19 (0) pain Injection site 13 (0) 13 (0) 10 (0) 12 (0) 11 (0) 10 (0) erythema Injection site 12 (0) 10 (<1) 10 (0) 9 (0) 7 (0) 8 (0) induration Injection site 4 (0) 3 (<1) 5 (0) 5 (0) 4 (0) 5 (0) ecchymosis Systemic Adverse Reactions Headache 19 (<1) 19 (<1) 19 (<1) 9 (<1) 9 (<1) 8 (<1) Fatigue 18 (<1) 22 (<1) 16 (2) 9 (<1) 11 (<1) 9 (<1) Myalgia 15 (<1) 15 (<1) 15 (1) 8 (<1) 9 (<1) 8 (<1) Nausea 10 (<1) 7 (<1) 9 (1) 4 (<1) 4 (0) 4 (<1) Arthralgia 8 (<1) 8 (0) 10 (<1) 6 (<1) 5 (<1) 7 (<1) Loss of 8 (<1) 9 (<1) 8 (<1) 4 (<1) 5 (0) 4 (<1) appetite
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/2025-2026-flucelvax-tiv-product-monograph-april-17-2025.pdf -
CSL Seqirus is a global influenza vaccine company developing innovative solutions to ensure epidemic and pandemic preparedness throughout the world.
https://www.cslseqirus.ca/our-company -
CSL Seqirus is Fully Prepared to Implement the WHO’s Trivalent Influenza Vaccines Strain Selection for the 2025/26 Canadian Influenza Season
https://www.cslseqirus.ca/news/canadian-audience-only -
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.cslseqirus.ca/news/news-archives -
Learn more about how we're leveraging cutting-edge technology and proven expertise to develop influenza vaccines and respond to pandemic threats.
https://www.cslseqirus.ca/ -
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.cslseqirus.ca/news -
CSL Seqirus, a business of CSL (ASX: CSL), today announced new data from five studies reinforcing the importance of seasonal influenza vaccination and exhibiting the benefits of cell-based influenza vaccines among people aged 6 months to 64 years.
https://www.cslseqirus.ca/news/idweek-2024 -
CSL Seqirus, a business of CSL (ASX: CSL), announced data from a range of real-world evidence (RWE) studies, highlighting the important role influenza vaccination plays in protecting public health.
https://www.cslseqirus.ca/news/options